Galapagos NV
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
06 mar 2015 - 07:30
Statutory name
Galapagos NV
Title
Galapagos reports 2014 financial results
Comments
Robust clinical programs in inflammation and cystic fibrosis supported by a strong financial position
Key 2014 results:
Group revenues €108m, including €18m from discontinued operations
Group net profit €33m resulting from divestment of service operations
Year-end cash €198m, including €11m in restricted cash
Filgotinib: recruitment completed for phase 2B studies DARWIN 1 and 2; 98% of eligible patients enrolled in long term extension DARWIN 3
Cystic fibrosis program in the clinic
GLPG1205 in Phase 2A study for ulcerative colitis
Date last update: 29 April 2025